Citations

Clear

941 citation(s) found for "Tefferi, A".

Calculator‐free point‐of‐care prognostication in myelodysplastic syndromes
Tefferi, Ayalew , Hanson, Curtis A. , Pardanani, Animesh , Gangat, Naseema , Gangat, Naseema , Ketterling, Rhett P.

Mayo Clinic

American Journal of Hematology | January 14, 2019 | Volume: 94 | Issue: 4 | Pages: No page available

10.1002/ajh.25400 | PMID 30637785 Get It

Refractory anemia with ring sideroblasts (RARS) and RARS with thrombocytosis: “2019 Update on Diagnosis, Risk‐stratification, and Management”
Patnaik, Mrinal M. , Tefferi, Ayalew

Mayo Clinic

American Journal of Hematology | January 9, 2019 | Volume: 94 | Issue: 4 | Pages: 475-488

10.1002/ajh.25397 | PMID 30618061 Get It

Disease OverviewRing sideroblasts (RS) are erythroid precursors with abnormal perinuclear mitochondrial iron accumulation. Two myeloid neoplasms defined by the presence of RS, include refractory anemia with ring sideroblasts (RARS), now classified under myelodysplastic syndromes with RS (MDS‐RS) and RARS with thrombocytosis (RARS‐T); now called myelodysplastic/myeloproliferative neoplasm with RS and thrombocytosis (MDS/MPN‐RS‐T).DiagnosisMDS‐RS is a lower‐risk MDS, with single or multilineage dysplasia (SLD/MLD), <5% bone marrow (BM) blasts and ≥ 15% BM RS (≥5% in the presence of SF3B1 mutations). MDS/MPN‐RS‐T, now a formal entity in the MDS/MPN overlap syndromes, has diagnostic features of MDS‐RS‐SLD, along with a platelet count ≥450 × 10(9)/L and large atypical megakaryocytes.Mutations and KaryotypeMutations in SF3B1 are seen in ≥80% of patients with MDS‐RS‐SLD and MDS/MPN‐RS‐T, and strongly correlate with the presence of BM RS; MDS/MPN‐RS‐T patients also demonstrate JAK2V617F, ASXL1, DNMT3A, SETBP1, and TET2 mutations. Cytogenetic abnormalities are uncommon in both.Risk stratificationMost patients with MDS‐RS‐SLD are stratified into lower‐risk groups by the revised‐IPSS. Disease outcome in MDS/MPN‐RS‐T is better than that of MDS‐RS‐SLD, but worse than that of essential thrombocythemia. Both diseases have a low risk of leukemic transformation.TreatmentAnemia and iron overload are complications seen in both and are managed similar to lower‐risk MDS and MPN. The advent of luspatercept, a first‐in‐class erythroid maturation agent will tremendously boost the ability to manage anemia. Aspirin therapy is reasonable in MDS/MPN‐RS‐T, especially in the presence of JAK2V617F, but the value of platelet‐lowering drugs remains uncertain.
The germline JAK2 GGCC (46/1) haplotype and survival among 414 molecularly‐annotated patients with primary myelofibrosis
Tefferi, Ayalew , Mudireddy, Mythri , Finke, Christy M. , Hanson, Curtis A. , Gangat, Naseema , Pardanani, Animesh , Lasho, Terra L. , Mudireddy, Mythri , Gangat, Naseema , Ketterling, Rhett P.

Mayo Clinic

American Journal of Hematology | December 5, 2018 | Volume: 94 | Issue: 3 | Pages: 299-305

10.1002/ajh.25349 | PMID 30516848 Get It

Abstract JAK2 mutations in myeloproliferative neoplasms (MPNs) are associated with the germline GGCC (46/1) haplotype. In 2010, we reported an association between shortened survival in primary myelofibrosis (PMF) and nullizygosity for the JAK2 46/1 haplotype. In the current study, we have increased the number of informative cases from 130 to 414 (median age 63 years; 63% males), in order to revisit with the phenotypic and prognostic relevance of the JAK2 46/1 haplotype in PMF. JAK2 46/1 haplotype was documented in 69% of the study patients, including 25% in homozygous and 44% in heterozygous state. Driver mutation frequency in patients homozygous/heterozygous/nullizygous for the 46/1 haplotype was 78%/60%/56% JAK2, 10%/20%/18% type 1‐like CALR, 3%/2%/5% type 2‐like CALR, 4%/8%/7% MPL, and 6%/10%/14% triple‐negative (P = .02). In univariate analysis, nullizygosity for the JAK2 46/1 haplotype was associated with inferior overall survival (HR 1.5, 95% CI 1.1‐1.9), most pronounced in JAK2 (P <.001), as opposed to CALR/MPL mutated (P = .48) or triple‐negative cases (P = .27). Multivariable analysis that included karyotype, driver mutational status and high‐molecular risk mutations confirmed the independent prognostic contribution of nullizygosity for the 46/1 haplotype (P = .02; HR 1.4, 95% CI 1.1‐1.8). Nullizygosity for 46/1 also remained significant in the context of the genetically‐inspired GIPSS risk model (P = .04), but not in the context of the integrated genetics‐clinical MIPSS70+ version 2.0 model (P = .4). Leukemia‐free survival was not affected by the 46/1 haplotype (P = .6). The current study confirms the association of nullizygosity for the JAK2 GGCC (46/1) haplotype with inferior survival in JAK2‐mutated PMF.
20+ Years and alive with primary myelofibrosis: Phenotypic signature of very long‐lived patients
Penna, Domenico , Finke, Christy M. , Vallapureddy, Rangit, Hanson, Curtis A. , Pardanani, Animesh , Gangat, Naseema , Tefferi, Ayalew , Lasho, Terra L. , Vallapureddy, Rangit R, Gangat, Naseema , Tefferi, Ayalew , Ketterling, Rhett P.

Mayo Clinic

American Journal of Hematology | December 5, 2018 | Volume: 94 | Issue: 3 | Pages: 286-290

10.1002/ajh.25351 | PMID 30516867 Get It

AbstractIn the last decade, several prognostic models for primary myelofibrosis (PMF) have been introduced and shown to be effective in predicting overall survival. The main objective for this study was to identify clinical and genetic markers of very long (20+ years) survival in PMF. A total of 1282 patients with PMF were considered (median age 65 years, range 19‐92; 63% males); 26 (2%) patients (median age 51 years, range 28‐71; 38% males) survived their disease for at least 20 years (long‐lived patients) and 626 (49%) patients (median age 68 years, range 27‐92; 66% males) died within 5 years of their diagnosis (short‐lived patients). Multivariable logistic regression analysis identified 7 variables that were associated with survival beyond 20 years: age ≤ 70 years (P = .002); female sex (P = .03); hemoglobin level ≥ 10 g/dL for women and ≥ 11 g/dL for men (P = .03), leukocyte count ≤25 × 109/L (P = .009), platelet count ≥100 × 109/L (P = .002), circulating blasts <2% (P = .03) and absence of constitutional symptoms (P = .04). Five‐year mortality was independently predicted by high‐molecular risk mutations (P < .001); unfavorable or very high risk karyotype (P < .001); absence of type 1/like CALR mutation (P < .001); age > 70 years (P < .001); constitutional symptoms (P < .001); hemoglobin level < 10 g/dL for women and < 11 g/dL for men (P < .001); leukocyte count >25 × 109/L (P = .004); and circulating blasts ≥2% (P = .001). This study suggests that genetic risk factors in PMF are associated with early mortality while survival beyond 20 years could be predicted by easily accessible clinical variables, including age, sex, blood counts, and symptoms.
Mutations and prognosis in myeloproliferative neoplasms
Tefferi, Ayalew , Pardanani, Animesh

Mayo Clinic

Leukemia & Lymphoma | November 14, 2018 | Volume: 60 | Issue: 5 | Pages: 1112-1113

10.1080/10428194.2018.1537490 | PMID 30424706 Get It

Mayo alliance prognostic system for mastocytosis: clinical and hybrid clinical-molecular models
Pardanani, Animesh , Shah, Sahrish, Mannelli, Francesco , Elala, Yoseph, Patnaik, Mrinal M. , Gangat, Naseema , Reichard, Kaaren K. , Hanson, Curtis A. , Tefferi, Ayalew , Elala, Yoseph C, Lasho, Terra L. , Mannelli, Francesco , Guglielmelli, Paola , Ketterling, Rhett P. , Vannucchi, Alessandro M.

Mayo Clinic

Blood Advances | November 9, 2018 | Volume: 2 | Issue: 21 | Pages: 2964-2972

10.1182/bloodadvances.2018026245 | PMID 30413432 Get It

Abstract Systemic mastocytosis (SM) is a clinically heterogeneous disease with prognosis chiefly assigned based on World Health Organization (WHO) morphologic subclassification. We assessed the feasibility of developing contemporary risk models for SM based on clinical and integrated clinical-genetics information. Diagnosis of SM was per WHO criteria, and karyotype and next-generation sequencing data were available in a subset of the total 580 patients (median age, 55 years; range, 18-88 years) seen at the Mayo Clinic between 1968 and 2015. Morphologic subcategories were indolent/smoldering in 291 (50%) and “advanced” in 289 (50%): SM with an associated hematological neoplasm in 199, aggressive SM in 85, and mast cell leukemia in 5. Multivariable analysis of clinical variables identified age &gt;60 years, advanced SM, thrombocytopenia &lt;150 × 109/L, anemia below sex-adjusted normal, and increased alkaline phosphatase (ALP) as independent risk factors for survival; respective hazard ratios (HRs) 95% confidence intervals (95% CIs) were 2.5 (1.9-3.4), 2.7 (1.8-4.0), 2.5 (1.9-3.4), 2.2 (1.6-3.1), and 2.1 (1.5-3.0). In addition, ASXL1 (HR, 4.5; 95% CI, 2.6-7.6), RUNX1 (HR, 4.3; 95% CI, 1.3-10.8), and NRAS (HR, 5.0, 95% CI, 1.5-13.2) mutations were independently associated with inferior survival. Combined clinical, cytogenetic, and molecular risk factor analysis confirmed the independent prognostic contribution of adverse mutations (2.6, 1.6-4.4), advanced SM (4.0, 1.8-10.0), thrombocytopenia (2.8, 1.7-4.5), increased ALP (2.1, 1.2-4.0), and age &gt;60 years (2.2, 1.3-3.6). These data were subsequently used to develop clinical and hybrid clinical-molecular risk models. The current study advances 2 complementary risk models for SM and highlights the independent prognostic contribution of mutations.
Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk‐stratification and management
Tefferi, Ayalew , Barbui, Tiziano , Barbui, Tiziano

Mayo Clinic

American Journal of Hematology | October 5, 2018 | Volume: 94 | Issue: 1 | Pages: 133-143

10.1002/ajh.25303 | PMID 30281843 Get It

Abstract Disease Overview: Polycythemia vera (PV) and essential thrombocythemia (ET) are myeloproliferative neoplasms respectively characterized by erythrocytosis and thrombocytosis; other disease features include leukocytosis, splenomegaly, thrombosis, bleeding, microcirculatory symptoms, pruritus, and risk of leukemic or fibrotic transformation. Diagnosis: Bone marrow morphology remains the cornerstone of diagnosis. In addition, the presence of JAK2 mutation is expected in PV while approximately 90% of patients with ET express mutually exclusive JAK2, CALR, or myeloproliferative leukemia mutations. In ET, it is most important to exclude the possibility of prefibrotic myelofibrosis. Survival: Median survivals are 14 years for PV and 20 years for ET; the corresponding values for younger patients are 24 and 33 years. Certain mutations (mostly spliceosome) and abnormal karyotype might compromise survival in PV and ET. Life‐expectancy in ET is inferior to the control population. Driver mutations have not been shown to affect survival in ET. Risk of thrombosis is higher in JAK2‐mutated ET. Leukemic transformation rates at 10 years are estimated at <1% for ET and 3% for PV. Thrombosis Risk: In PV, 2 risk categories are considered: high (age > 60 years or thrombosis history present) and low (absence of both risk factors); in ET, 4 risk categories are considered: very low (age ≤ 60 years, no thrombosis history, JAK2 wild‐type), low (same as very low but JAK2 mutation present), intermediate (age > 60 years, no thrombosis history, JAK2 wild‐type) and high (thrombosis history present or age > 60 years with JAK2 mutation). Risk‐Adapted Therapy: The main goal of therapy in both PV and ET is to prevent thrombohemorrhagic complications. All patients with PV require phlebotomy to keep hematocrit below 45% and once‐ or twice‐daily aspirin (81 mg), in the absence of contraindications. Very low‐risk ET might not require therapy while aspirin therapy is advised for low‐risk disease. Cytoreductive therapy is recommended for high‐risk ET and PV but it is not mandatory for intermediate‐risk ET. First‐line drug of choice for cytoreductive therapy, in both ET and PV, is hydroxyurea and second‐line drugs of choice are interferon‐α and busulfan. We do not recommend treatment with ruxolutinib in PV, unless in the presence of severe and protracted pruritus or marked splenomegaly that is not responding to the aforementioned drugs.
Smoldering mastocytosis: Survival comparisons with indolent and aggressive mastocytosis
Tefferi, Ayalew , Shah, Sahrish, Reichard, Kaaren K. , Hanson, Curtis A. , Pardanani, Animesh

Mayo Clinic

American Journal of Hematology | October 5, 2018 | Volume: 94 | Issue: 1 | Pages: No page available

10.1002/ajh.25302 | PMID 30281840 Get It

Decreased survival and increased rate of fibrotic progression in essential thrombocythemia chronicled after the FDA approval date of anagrelide
Tefferi, Ayalew , Vallapureddy, Rangit, Begna, Kebede H. , Patnaik, Mrinal M. , Elliott, Michelle A. , Hook, C. Christopher , Wolanskyj, Alexandra P. , Hanson, Curtis A. , Pardanani, Animesh , Gangat, Naseema , Szuber, Natasha , Vallapureddy, Rangit R, Begna, Kebede , Patnaik, Mrinal , Elliott, Michelle , Gangat, Naseema , Wolanskyj-Spinner, Alexandra P , Ketterling, Rhett P.

Mayo Clinic

American Journal of Hematology | September 25, 2018 | Volume: 94 | Issue: 1 | Pages: 5-9

10.1002/ajh.25294 | PMID 30252953 Get It

AbstractFirst‐line cytoreductive drug of choice in high risk essential thrombocythemia (ET) is currently hydroxyurea, a practice based on the results of a randomized study; second‐line drugs of choice include pegylated interferon‐α, busulfan and anagrelide. Anagrelide clinical trials were pioneered by the late Murray N. Silverstein (1928‐1998) of the Mayo Clinic whose studies led to FDA approval in March 1997. The current study represents a retrospective examination of the potential impact of anagrelide therapy on survival and disease complications in ET. 1076 patients with ET were considered (median age 58 years; females 63%); risk distribution, according to the international prognostic score for ET (IPSET), was 28% high, 42% intermediate, and 30% low. Overall (OS), myelofibrosis‐free (MFFS) and thrombosis‐free survival data were compared for ET patients diagnosed before and after the 1997 FDA approval date for anagrelide; a significant difference was apparent in OS (P = .006; HR 1.4, 95% CI 1.1‐1.7) and MFFS (P < .001; HR 4.2, 95% CI 2.7‐6.5), in favor of patients diagnosed prior to 1997; the difference was sustained during multivariable analysis that included IPSET. Similarly stratified survival data in polycythemia vera (n = 665) and primary myelofibrosis (n = 1282) showed no similar impact on survival (P = .3 and .17, respectively). The current study represents a retrospective analysis and suggests significantly decreased OS and MFFS in ET patients diagnosed after the FDA approval date of anagrelide. Whether or not anagrelide therapy was to blame for the worsening of OS and MFFS over time cannot be assumed and requires validation in a prospective study.
A novel predictive model of outcome in acute myeloid leukemia without favorable karyotype based on treatment strategy, karyotype and FLT3‐ITD mutational status
Begna, Kebede H. , Ali, Walid , Gangat, Naseema , Elliott, Michelle A. , Al‐Kali, Aref , Litzow, Mark R. , Hook, C. Christopher , Wolanskyj, Alexandra P. , Patnaik, Mrinal M. , Pardanani, Animesh , Zblewski, Darci, Chen, Dong , He, Rong , Viswanatha, David S., Hanson, Curtis A. , Tefferi, Ayalew , Patnaik, Mrinal , Zblewski, Darci L, Chen, Dong , Viswanatha, David, Tefferi, Ayalew , Wolanskyj-Spinner, Alexandra P , Hogan, William J. , Ketterling, Rhett P.

Mayo Clinic

American Journal of Hematology | September 19, 2018 | Volume: 93 | Issue: 12 | Pages: No page available

10.1002/ajh.25290 | PMID 30230610 Get It